- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02860585
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation (BREAST-HDCT)
September 25, 2017 updated by: Institut Paoli-Calmettes
The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
235
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Marseille, France, 13009
- Institut Paoli-Calmettes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
female patients treated for Metastatic breast Cancer with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation at the Institut Paoli-Calmettesbetween 2003 and 2012
Description
Inclusion Criteria:
- Age>18 years
- Metastatic breast Cancer
- Treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation between 2003 and 2012
Exclusion Criteria:
- Lack of follow-up data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival according to Immunohistochemical subtypes .
Time Frame: 8 years
|
8 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free Survival according to Immunohistochemical subtypes .
Time Frame: 8 years
|
8 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Christian Chabannon, MD,PhD, Institut Paoli-Calmettes
- Principal Investigator: Anthony Gonçalves, MD,PhD, Institut Paoli-Calmettes
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 27, 2013
Primary Completion (Actual)
February 29, 2016
Study Completion (Actual)
February 29, 2016
Study Registration Dates
First Submitted
August 4, 2016
First Submitted That Met QC Criteria
August 4, 2016
First Posted (Estimate)
August 9, 2016
Study Record Updates
Last Update Posted (Actual)
September 26, 2017
Last Update Submitted That Met QC Criteria
September 25, 2017
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BREAST-HDCT-IPC 2014-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteConquer Cancer FoundationRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
-
MedSIRHoffmann-La RocheCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast CancerSpain, France, United Kingdom, Germany, Italy